Cancer remains one of the biggest health challenges of our lifetime. Millions of people globally receive a cancer diagnosis each year — in the United States, that’s about one diagnosis every 30 ...

Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment. A new Phase 2 clinical ...

A new drug combination has been shown to double survival time for patients with a particularly aggressive type of colorectal ...

Pfizer (NYSE:PFE) said on Friday that a late-stage trial evaluating a Braftovi combination increased survival time for patients with metastatic colorectal cancer with a BRAF V600E mutation. In the ...

In talks at the annual meeting of the American Society of Clinical Oncology (ASCO), experts from Roswell Park Comprehensive Cancer Center will give remarks on racial and ethnic disparities in outcomes ...

Onc.AI, a digital health company developing AI-powered oncology clinical management solutions, today announced that new validation study results from research collaborations with Pfizer, Baylor Scott ...